Prostate Cancer Trial, Recruiting (NCT07115992)

Prostate Cancer Trial, Recruiting NCT07115992 Sponsor: Ruijin Hospital Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07115992 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Men between 18 and 80 years of age who have signed and dated a consent form agreeing to take part.
Men who are able to commit to following the study's procedures throughout the entire trial.
Men who are healthy enough to undergo the procedures involved in the study, including a specialised prostate scan (PSMA PET imaging), robotic surgery to remove the prostate, and radiation treatment to the pelvic area.
Men who have been diagnosed with localised intermediate- or high-risk prostate cancer that has not spread, confirmed through biopsy, a PSA blood test, and a specialised scan (PSMA PET/MRI).
Men whose cancer risk score on a specific medical tool (the Briganti 2017 nomogram) is 7% or higher (confirm with trial site).
Men whose cancer has been assessed as suitable for surgical removal of the prostate.
Men whose cancer falls into specific intermediate-risk or high-risk categories based on PSA level, biopsy grading, or tumour stage (confirm exact categories with trial site).

Who may not be able to join:

Men who have previously received any treatment for prostate cancer, including radiation, chemotherapy, or hormone therapy.
Men whose biopsy shows a less common type of prostate cancer that is not the standard form (non-acinar adenocarcinoma).
Men whose scans show the cancer has already spread to nearby lymph nodes, surrounding tissue, or other parts of the body.
Men who have previously had pelvic lymph node surgery or radiation to the pelvic area.
Men who have had another cancer diagnosed within the past 5 years.
Men who have medical reasons that make prostate surgery unsafe or unsuitable.
Men who have medical reasons that make radiation therapy unsafe or unsuitable, as determined by a radiation specialist.
Men who have a severe allergy to the substances used in the PSMA PET scan.
Men who have any other condition that would prevent them from safely having a PSMA PET scan.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07115992

Sponsor: Ruijin Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Prostate Cancer

More information: https://clinicaltrials.gov/study/NCT07115992

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Men between 18 and 80 years of age who have signed and dated a consent form agreeing to take part.
Men who are able to commit to following the study's procedures throughout the entire trial.
Men who are healthy enough to undergo the procedures involved in the study, including a specialised prostate scan (PSMA PET imaging), robotic surgery to remove the prostate, and radiation treatment to the pelvic area.
Men who have been diagnosed with localised intermediate- or high-risk prostate cancer that has not spread, confirmed through biopsy, a PSA blood test, and a specialised scan (PSMA PET/MRI).
Men whose cancer risk score on a specific medical tool (the Briganti 2017 nomogram) is 7% or higher (confirm with trial site).
Men whose cancer has been assessed as suitable for surgical removal of the prostate.
Men whose cancer falls into specific intermediate-risk or high-risk categories based on PSA level, biopsy grading, or tumour stage (confirm exact categories with trial site).

Who may not be able to join:

Men who have previously received any treatment for prostate cancer, including radiation, chemotherapy, or hormone therapy.
Men whose biopsy shows a less common type of prostate cancer that is not the standard form (non-acinar adenocarcinoma).
Men whose scans show the cancer has already spread to nearby lymph nodes, surrounding tissue, or other parts of the body.
Men who have previously had pelvic lymph node surgery or radiation to the pelvic area.
Men who have had another cancer diagnosed within the past 5 years.
Men who have medical reasons that make prostate surgery unsafe or unsuitable.
Men who have medical reasons that make radiation therapy unsafe or unsuitable, as determined by a radiation specialist.
Men who have a severe allergy to the substances used in the PSMA PET scan.
Men who have any other condition that would prevent them from safely having a PSMA PET scan.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Ruijin Hospital

Registry

ClinicalTrials.gov

Start date

30 July 2025

Est. completion

29 February 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

2-year Biochemical-recurrence Free Survival rate (2-year BFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov